Bvf I Gp LLC insider trades
Bvf I Gp LLC has filed 7 Form 4s with the SEC that we hold, for MRUS (10% owner), 4D Molecular Therapeutics, Inc. (FDMT) (Reporting owner), Kymera Therapeutics, Inc. (KYMR) (Director) and MoonLake Immunotherapeutics (MLTX) (Director, 10% owner), among 6 companies in all. Across all of them we count 4 purchases worth $990.8K and 12 sales worth $176.6M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a sale of 1,030,589 shares of MoonLake Immunotherapeutics worth $51.5M, dated 2024-10-04. The first filing on our record is dated 2021-07-07 and the latest 2024-12-17.
MRUS
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-02 | S, sale reported on Form 4 | 928,739 | $19.3M | 2021-07-07 |
| 2021-07-02 | S, sale reported on Form 4 | 1,106,478 | $23.0M | 2021-07-07 |
| 2021-07-02 | S, sale reported on Form 4 | 150,805 | $3.1M | 2021-07-07 |
| 2021-10-07 | S, sale reported on Form 4 | 530,999 | $14.6M | 2021-10-08 |
| 2021-10-07 | S, sale reported on Form 4 | 69,534 | $1.9M | 2021-10-08 |
| 2021-10-07 | S, sale reported on Form 4 | 384,914 | $10.6M | 2021-10-08 |
| 2021-10-08 | S, sale reported on Form 4 | 80,011 | $2.2M | 2021-10-08 |
| 2021-10-08 | S, sale reported on Form 4 | 8,929 | $248.1K | 2021-10-08 |
| 2021-10-08 | S, sale reported on Form 4 | 58,327 | $1.6M | 2021-10-08 |
4D Molecular Therapeutics, Inc. (FDMT)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Kymera Therapeutics, Inc. (KYMR)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
MoonLake Immunotherapeutics (MLTX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-10-04 | S, sale reported on Form 4 | 836,862 | $41.8M | 2024-10-08 |
| 2024-10-04 | S, sale reported on Form 4 | 132,549 | $6.6M | 2024-10-08 |
| 2024-10-04 | S, sale reported on Form 4 | 1,030,589 | $51.5M | 2024-10-08 |
Palvella Therapeutics, INC. (PVLA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
XOMA Royalty Corp (XOMA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-09-14 | P, purchase reported on Form 4 | 26,441 | $456.1K | 2022-09-16 |
| 2022-09-15 | P, purchase reported on Form 4 | 5,575 | $100.1K | 2022-09-16 |
| 2022-09-16 | P, purchase reported on Form 4 | 13,396 | $239.7K | 2022-09-16 |
| 2022-09-16 | P, purchase reported on Form 4 | 10,897 | $194.9K | 2022-09-16 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1803805) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms